Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr 5;12(2):52.
doi: 10.3390/ph12020052.

2018 FDA Tides Harvest

Danah Al Shaer  1   2 , Othman Al Musaimi  3   4 , Fernando Albericio  5   6 , Beatriz G de la Torre  7
Affiliations
Review

2018 FDA Tides Harvest

Danah Al Shaer et al. Pharmaceuticals (Basel). .

Abstract

In 2018, the United States Food and Drug Administration (FDA) approved a total of 59 new drugs, three of them (5%) are TIDES (or also, -tides), two oligonucleotides and one peptide. Herein, the three TIDES approved are analyzed in terms of medical target, mode of action, chemical structure, and economics.

Keywords: Lutathera; Onpattro; Tegsedi; dotatate; drugs; inotersen; oligonucleotides; patisiran; peptides; pharmaceutical market.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
127 new drugs approved by the United States Federal Food and Drug Administration (FDA) from 2016 to 2018, and classified on the basis of chemical structure [2,4,6].
Figure 2
Figure 2
Patisiran sequence and chemical composition.
Figure 3
Figure 3
Inotersen sequence and chemical composition.
Figure 4
Figure 4
[177Lu]Lu-DOTA-TATE chemical structure.
See this image and copyright information in PMC

References

    1. Mullard A. 2016 FDA drug approvals. Nat. Rev. Drug Discov. 2017;16:73–76. doi: 10.1038/nrd.2017.14. - DOI - PubMed
    1. Torre B.G., Albericio F. The pharmaceutical industry in 2016. An analysis of FDA drug approvals from a perspective of the molecule type. Molecules. 2017;22 doi: 10.3390/molecules22030368. - DOI - PMC - PubMed
    1. Mullard A. 2017 FDA drug approvals. Nat. Rev. Drug Discov. 2018;17:81–85. doi: 10.1038/nrd.2018.4. - DOI - PubMed
    1. De la Torre B.G., Albericio F. The pharmaceutical industry in 2017. An analysis of FDA drug approvals from the perspective of molecules. Molecules. 2018;23 doi: 10.3390/molecules23030533. - DOI - PMC - PubMed
    1. Mullard A. 2018 FDA drug approvals. Nat. Rev. Drug Discov. 2019;18:85–89. doi: 10.1038/d41573-019-00014-x. - DOI - PubMed

LinkOut - more resources